Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

PHASE 1B TRIAL OF AVL-292, A COVALENT INHIBITOR OF BRUTON'S TYROSINE KINASE (BTK), IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND B-NON-HODGKIN LYMPHOMA (B-NHL)
Дата публикации: 27-08-2026 00:00:00

PHASE 1B TRIAL OF AVL-292, A COVALENT INHIBITOR OF BRUTON'S TYROSINE KINASE (BTK), IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND B-NON-HODGKIN LYMPHOMA (B-NHL)

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)0527-08-2026
2ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY02.327-08-2026
3RANDOMIZED COMPARISON OF IBRUTINIB <i>VERSUS</i> OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE(™) TRIAL02.2927-08-2026
4Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors05.2127-08-2026
5Highly Specific Inhibitor for Syk Induces Chronic Lymphocytic Leukemia Cell Apoptosis02.527-08-2026
6Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory iNHL and CLL02.1627-08-2026
7Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer014.2801-01-2025
8Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer01028-07-2026
9New study reveals how blood cancers outsmart BTK-targeted therapies08.128-07-2026
10Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer018.8530-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.62. Источник: escholarship.org.